|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,449.50 GBX | -2.06% |
|
-4.83% | +7.65% |
| 11:27pm | Kennedy's new US vaccine panel to discuss measles shot for children | RE |
| 11:27pm | Kennedy's new US vaccine panel to discuss measles shot for children | RE |
| Capitalization | 58.7B 79.09B 68.66B 64.61B 108B 6,834B 121B 759B 293B 3,126B 297B 290B 11,436B | P/E ratio 2025 * |
10.1x | P/E ratio 2026 * | 8.92x |
|---|---|---|---|---|---|
| Enterprise value | 71.82B 96.76B 84.01B 79.05B 132B 8,362B 148B 928B 359B 3,825B 363B 355B 13,991B | EV / Sales 2025 * |
2.23x | EV / Sales 2026 * | 2.03x |
| Free-Float |
94.52% | Yield 2025 * |
4.48% | Yield 2026 * | 4.78% |
More valuation ratios
* Estimated data
More news
Last Transcript: GSK plc
More recommendations
More press releases
| 1 day | -2.06% | ||
| 1 week | -4.83% | ||
| Current month | -3.82% | ||
| 1 month | +3.94% | ||
| 3 months | -5.35% | ||
| 6 months | +8.66% | ||
| Current year | +7.65% |
| 1 week | 1,443.5 |  | 1,554.5 |
| 1 month | 1,401 | | 1,557 |
| Current year | 1,242.5 | | 1,560.5 |
| 1 year | 1,242.5 | | 1,678.68 |
| 3 years | 1,242.5 | | 2,280.5 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 56 | 31/03/2017 |
Julie Brown
DFI | Director of Finance/CFO | 63 | 30/04/2023 |
James Ford
CMP | Compliance Officer | - | 31/07/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
BRD | Director/Board Member | 56 | 31/12/2016 |
Hal Barron
BRD | Director/Board Member | 63 | 31/12/2017 |
Jonathan Symonds
CHM | Chairman | 67 | 31/08/2019 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 3.15% | 21 M€ | +0.30% | - | |
| 2.97% | 57 M€ | +12.19% | - | |
| 2.51% | 7 M€ | +14.74% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.06% | -4.83% | -10.08% | -31.12% | 79.09B | ||
| -0.78% | -2.92% | -11.94% | +169.86% | 705B | ||
| -1.08% | -2.92% | +3.49% | -11.05% | 363B | ||
| -1.13% | -6.62% | -50.83% | +29.17% | 331B | ||
| +0.01% | -3.14% | +8.25% | +34.14% | 328B | ||
| -0.96% | -4.00% | +4.52% | -14.59% | 254B | ||
| -0.63% | -2.09% | +1.95% | +20.25% | 228B | ||
| -1.07% | -3.28% | -15.05% | +6.29% | 220B | ||
| +1.29% | -1.28% | -38.05% | -6.30% | 199B | ||
| -0.19% | -0.79% | -5.39% | +23.34% | 156B | ||
| Average | -0.46% | -3.24% | -11.31% | +22.00% | 286.25B | |
| Weighted average by Cap. | -0.32% | -3.06% | -11.25% | +48.47% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 32.24B 43.43B 37.7B 35.48B 59.42B 3,753B 66.59B 417B 161B 1,717B 163B 160B 6,280B | 34.06B 45.89B 39.84B 37.49B 62.79B 3,966B 70.37B 440B 170B 1,814B 172B 169B 6,636B |
| Net income | 5.78B 7.78B 6.76B 6.36B 10.65B 673B 11.93B 74.65B 28.85B 308B 29.2B 28.58B 1,125B | 6.52B 8.78B 7.62B 7.17B 12.01B 759B 13.46B 84.22B 32.55B 347B 32.95B 32.25B 1,270B |
| Net Debt | 13.12B 17.67B 15.34B 14.44B 24.18B 1,527B 27.1B 170B 65.51B 699B 66.31B 64.91B 2,555B | 10.37B 13.97B 12.13B 11.41B 19.12B 1,207B 21.42B 134B 51.79B 552B 52.42B 51.31B 2,020B |
More financial data
* Estimated data
Employees
68,629
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/06/25 | 1,449.50 p | -2.06% | 8,649,492 |
| 17/06/25 | 1,480.00 p | -0.37% | 12,363,190 |
| 16/06/25 | 1,485.50 p | -1.72% | 9,117,271 |
| 13/06/25 | 1,511.50 p | -2.45% | 9,549,960 |
| 12/06/25 | 1,549.50 p | +1.74% | 7,395,989 |
Delayed Quote London S.E., June 18, 2025 at 04:35 pm
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
14.50GBP
Average target price
16.66GBP
Spread / Average Target
+14.96%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition